| 000 | 01758 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250517171646.0 | ||
| 264 | 0 | _c20171108 | |
| 008 | 201711s 0 0 eng d | ||
| 022 | _a1095-6859 | ||
| 024 | 7 |
_a10.1016/j.ygyno.2017.08.015 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMartin, Lainie P | |
| 245 | 0 | 0 |
_aCharacterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine. _h[electronic resource] |
| 260 |
_bGynecologic oncology _c11 2017 |
||
| 300 |
_a402-407 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xadministration & dosage |
| 650 | 0 | 4 | _aCarcinoma, Ovarian Epithelial |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFolate Receptor 1 _xbiosynthesis |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoconjugates _xadministration & dosage |
| 650 | 0 | 4 |
_aMaytansine _xadministration & dosage |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aMolecular Targeted Therapy |
| 650 | 0 | 4 |
_aNeoplasms, Glandular and Epithelial _xdrug therapy |
| 650 | 0 | 4 |
_aOvarian Neoplasms _xdrug therapy |
| 700 | 1 | _aKonner, Jason A | |
| 700 | 1 | _aMoore, Kathleen N | |
| 700 | 1 | _aSeward, Shelly M | |
| 700 | 1 | _aMatulonis, Ursula A | |
| 700 | 1 | _aPerez, Raymond P | |
| 700 | 1 | _aSu, Ying | |
| 700 | 1 | _aBerkenblit, Anna | |
| 700 | 1 | _aRuiz-Soto, Rodrigo | |
| 700 | 1 | _aBirrer, Michael J | |
| 773 | 0 |
_tGynecologic oncology _gvol. 147 _gno. 2 _gp. 402-407 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.ygyno.2017.08.015 _zAvailable from publisher's website |
| 999 |
_c27500460 _d27500460 |
||